Bioblast Pharma Ltd Company Profile (NASDAQ:ORPN)

About Bioblast Pharma Ltd (NASDAQ:ORPN)

Bioblast Pharma Ltd logoBioblast Pharma Ltd (BioBlast) is an Israel-based development-stage biopharmaceutical company. The Company is focused on the identification, licensing, acquisition, development and commercialization of drugs for rare and ultra-rare genetic and metabolic diseases. It focuses on therapeutic platforms that offer solutions for several diseases that share a common pathophysiological mechanism, which are the functional changes that accompany a particular syndrome or disease. It also focuses on diseases with severe and debilitating manifestations. The Company has several drug candidates in clinical or preclinical development targeting neuromuscular/central nervous system (CNS) and mitochondrial diseases. Its drug candidates include Trehalose IV Solution, BB-FA (Bioblast-Friedreich's ataxia) and BBrm-02. The Company's product candidate platforms include Protein Stabilizing Platform, Read-through Platform and Mitochondrial Protein Replacement Platform.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology
  • Sub-Industry: N/A
  • Symbol: NASDAQ:ORPN
  • CUSIP: N/A
  • Web: www.bioblast-pharma.com
Capitalization:
  • Market Cap: $7.38 million
  • Outstanding Shares: 16,391,000
Average Prices:
  • 50 Day Moving Avg: $0.53
  • 200 Day Moving Avg: $1.00
  • 52 Week Range: $0.41 - $2.24
P/E:
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -0.62
  • P/E Growth: 0.00
Sales & Book Value:
  • Annual Revenue: N/A
  • Price / Sales: N/A
  • Book Value: $0.53 per share
  • Price / Book: 0.85
Profitability:
  • EBIDTA: ($13,930,000.00)
  • Return on Equity: -52.90%
  • Return on Assets: -46.88%
Debt:
  • Current Ratio: 6.67%
  • Quick Ratio: 6.67%
Misc:
  • Average Volume: 82,100 shs.
  • Beta: 0.16
  • Short Ratio: 1.74
 

Frequently Asked Questions for Bioblast Pharma Ltd (NASDAQ:ORPN)

What is Bioblast Pharma Ltd's stock symbol?

Bioblast Pharma Ltd trades on the NASDAQ under the ticker symbol "ORPN."

How were Bioblast Pharma Ltd's earnings last quarter?

Bioblast Pharma Ltd (NASDAQ:ORPN) announced its earnings results on Thursday, August, 25th. The company reported ($0.22) earnings per share for the quarter, beating analysts' consensus estimates of ($0.27) by $0.05. During the same quarter in the previous year, the business earned ($0.26) EPS. View Bioblast Pharma Ltd's Earnings History.

Where is Bioblast Pharma Ltd's stock going? Where will Bioblast Pharma Ltd's stock price be in 2017?

2 equities research analysts have issued 1-year price targets for Bioblast Pharma Ltd's stock. Their forecasts range from $0.63 to $15.00. On average, they anticipate Bioblast Pharma Ltd's share price to reach $7.82 in the next year. View Analyst Ratings for Bioblast Pharma Ltd.

Who are some of Bioblast Pharma Ltd's key competitors?

Who owns Bioblast Pharma Ltd stock?

Bioblast Pharma Ltd's stock is owned by a variety of of retail and institutional investors. Top institutional shareholders include Sabby Management LLC (1.34%) and Renaissance Technologies LLC (0.97%). View Institutional Ownership Trends for Bioblast Pharma Ltd.

Who sold Bioblast Pharma Ltd stock? Who is selling Bioblast Pharma Ltd stock?

Bioblast Pharma Ltd's stock was sold by a variety of institutional investors in the last quarter, including Sabby Management LLC. View Insider Buying and Selling for Bioblast Pharma Ltd.

Who bought Bioblast Pharma Ltd stock? Who is buying Bioblast Pharma Ltd stock?

Bioblast Pharma Ltd's stock was purchased by a variety of institutional investors in the last quarter, including Renaissance Technologies LLC. View Insider Buying and Selling for Bioblast Pharma Ltd.

How do I buy Bioblast Pharma Ltd stock?

Shares of Bioblast Pharma Ltd can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

How much does a share of Bioblast Pharma Ltd stock cost?

One share of Bioblast Pharma Ltd stock can currently be purchased for approximately $0.45.

Analyst Ratings

Consensus Ratings for Bioblast Pharma Ltd (NASDAQ:ORPN) (?)
Ratings Breakdown: 2 Buy Ratings
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: $7.82 (1,636.28% upside)

Analysts' Ratings History for Bioblast Pharma Ltd (NASDAQ:ORPN)
Show:
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
4/28/2017S&P Equity ResearchBoost Price Target$0.56 -> $0.63LowView Rating Details
10/24/2016Roth CapitalSet Price TargetBuy$15.00N/AView Rating Details
7/11/2016Rodman & RenshawReiterated RatingBuyN/AView Rating Details
1/28/2016HC WainwrightInitiated CoverageBuy$25.00N/AView Rating Details
11/27/2015Oppenheimer Holdings Inc.Reiterated RatingOutperform$32.00N/AView Rating Details
(Data available from 5/26/2015 forward)

Earnings

Earnings History for Bioblast Pharma Ltd (NASDAQ:ORPN)
Earnings by Quarter for Bioblast Pharma Ltd (NASDAQ:ORPN)
Earnings History by Quarter for Bioblast Pharma Ltd (NASDAQ:ORPN)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
8/25/2016Q2($0.27)($0.22)ViewN/AView Earnings Details
5/25/2016Q1($0.29)($0.32)ViewN/AView Earnings Details
2/23/2016Q4($0.25)($0.34)ViewN/AView Earnings Details
11/17/2015Q3($0.29)($0.25)ViewN/AView Earnings Details
8/21/2015Q2($0.28)($0.26)ViewN/AView Earnings Details
5/19/2015Q115($0.25)($0.23)ViewN/AView Earnings Details
2/17/2015Q414($0.16)($0.22)ViewN/AView Earnings Details
11/21/2014($0.09)($0.16)ViewN/AView Earnings Details
8/29/2014Q214($0.09)($0.10)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Bioblast Pharma Ltd (NASDAQ:ORPN)
Current Year EPS Consensus Estimate: $-0.8200 EPS
Next Year EPS Consensus Estimate: $-0.7300 EPS

Dividends

Dividend History for Bioblast Pharma Ltd (NASDAQ:ORPN)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for Bioblast Pharma Ltd (NASDAQ:ORPN)
No insider trades for this company have been tracked by MarketBeat.com

Headlines

Headline Trends for Bioblast Pharma Ltd (NASDAQ:ORPN)
Latest Headlines for Bioblast Pharma Ltd (NASDAQ:ORPN)
Source:
DateHeadline
americanbankingnews.com logoBioblast Pharma (ORPN) Earns Daily Media Sentiment Score of 0.22
www.americanbankingnews.com - May 5 at 10:35 PM
americanbankingnews.com logoBioblast Pharma Ltd (ORPN) Expected to Announce Earnings of -$0.29 Per Share
www.americanbankingnews.com - May 3 at 5:58 PM
americanbankingnews.com logoBioblast Pharma (ORPN) Receiving Somewhat Positive Press Coverage, Study Shows
www.americanbankingnews.com - May 3 at 1:05 AM
americanbankingnews.com logoBioblast Pharma (ORPN) Given Daily News Impact Rating of -0.06
www.americanbankingnews.com - April 29 at 3:32 PM
americanbankingnews.com logoS&P Equity Research Increases Bioblast Pharma Ltd (ORPN) Price Target to $0.63
www.americanbankingnews.com - April 28 at 6:38 PM
americanbankingnews.com logoBioblast Pharma (ORPN) Getting Somewhat Positive Press Coverage, Report Shows
www.americanbankingnews.com - April 23 at 8:09 PM
americanbankingnews.com logoBioblast Pharma (ORPN) Receives Daily News Impact Rating of -0.12
www.americanbankingnews.com - April 20 at 1:25 PM
nasdaq.com logoBioblast Pharma Announces Plans in Response to Nasdaq Notifications Regarding Stockholders' Equity and Minimum ... - Nasdaq
www.nasdaq.com - April 20 at 12:08 AM
finance.yahoo.com logoBioblast Pharma Announces Plans in Response to Nasdaq Notifications Regarding Stockholders’ Equity and Minimum Bid Requirements
finance.yahoo.com - April 17 at 6:15 PM
americanbankingnews.com logoBioblast Pharma (ORPN) Earning Positive Media Coverage, Report Shows
www.americanbankingnews.com - April 17 at 6:13 PM
americanbankingnews.com logoBioblast Pharma (ORPN) Earns Daily Coverage Optimism Rating of 0.26
www.americanbankingnews.com - April 14 at 11:29 PM
americanbankingnews.com logoShort Interest in Bioblast Pharma Ltd (ORPN) Grows By 3.4%
www.americanbankingnews.com - April 13 at 12:34 PM
americanbankingnews.com logo Brokerages Expect Bioblast Pharma Ltd (ORPN) to Announce -$0.29 EPS
www.americanbankingnews.com - April 12 at 2:27 PM
finance.yahoo.com logoBioblast Pharma Announces Termination of Securities Offering
finance.yahoo.com - April 7 at 11:43 AM
finance.yahoo.com logoBioblast Announces Termination of Securities Offering
finance.yahoo.com - April 7 at 11:43 AM
americanbankingnews.com logo Analysts Set $9.00 Target Price for Bioblast Pharma Ltd (ORPN)
www.americanbankingnews.com - April 3 at 11:40 PM
us.rd.yahoo.com logoBioblast Pharma Announces Receipt of Nasdaq Notification Regarding Stockholders’ Equity
us.rd.yahoo.com - March 10 at 8:52 PM
finance.yahoo.com logoBIOBLAST PHARMA LTD. Financials
finance.yahoo.com - March 2 at 7:15 PM
us.rd.yahoo.com logoBioblast Pharma Reports Fourth Quarter and Year End 2016 Financial Results
us.rd.yahoo.com - February 24 at 8:45 AM
us.rd.yahoo.com logoBioblast Pharma Provides Clinical and Development Updates on Trehalose as a Potential Therapeutic for OPMD and Other Neurodegenerative Diseases
us.rd.yahoo.com - February 2 at 7:59 PM
us.rd.yahoo.com logo4:02 pm Bio Blast Pharma announces clinical update related to its proprietary intravenous (:IV) form of trehalose 90 mg/mL solution, which is being evaluated as a potential therapeutic, initially for oculopharyngeal muscular dystrophy
us.rd.yahoo.com - February 2 at 7:59 PM
finance.yahoo.com logoBioblast Pharma Provides Clinical and Development Updates on Trehalose as a Potential Therapeutic for OPMD and ... - Yahoo Finance
finance.yahoo.com - February 1 at 8:12 PM
finance.yahoo.com logoBioblast Pharma to Host Key Opinion Leader Lunch Focused on Orphan Neurological Diseases on February 2
finance.yahoo.com - January 27 at 12:21 AM
finance.yahoo.com logoBioblast (ORPN) SCA3 Drug Favorable in Phase IIa Study
finance.yahoo.com - January 19 at 11:44 PM
finance.yahoo.com logo8:01 am Bio Blast Pharma announces results of a 6-month open label Phase 2a study that also included an additional six-month follow-up period investigating trehalose in patients with Spinocerebellar Ataxia Type 3
finance.yahoo.com - January 18 at 7:39 PM
finance.yahoo.com logoBioblast Announces Phase 2a Results of Trehalose in Patients with Spinocerebellar Ataxia Type 3 (SCA3)
finance.yahoo.com - January 18 at 8:51 AM

Social

Chart

Bioblast Pharma Ltd (ORPN) Chart for Friday, May, 26, 2017

This page was last updated on 5/26/2017 by MarketBeat.com Staff